Agri-Varisty - Scientistsdiscover A New Cure

Download as pdf or txt
Download as pdf or txt
You are on page 1of 2

Discovery of a new cure for parturient hemoglobinuria in buffaloes and cows

Prof. (R) Dr. Ghulam Muhammad, Dr. M. Saqib, and Dr. Imaad Rashid
Department of Clinical Medicine and Surgery, University of Agriculture, Faisalabad, 38040
– Pakistan
Parturient hemoglobinuria (red water; colloquially known as Rut Mootra) is one of the
major and economically important metabolic diseases of dairy animals in Pakistan, India,
Egypt and elsewhere in the world. It is an acute disease of high yielding/pregnant buffaloes
and cows characterized by hypophosphatemia, intravascular hemolysis, hemoglobinuria
(reddish urine), anemia and death. Buffaloes in advanced pregnancy or within first few
months of calving are particularly susceptible. The disease is far more common in buffaloes
than in cows. In a survey conducted during 1996 in Punjab (Pakistan), 9% mortality due to
hemoglobinuria in buffaloes was reported which translated into estimated annual losses of
Rs. 490.0 millions. Given a steep escalation of prices of dairy animals over the past 19
years, the magnitude of current pecuniary losses associated with this disease may run into
several billion rupees annually in Pakistan.

Standard treatment of parturient hemoglobinuria is based on parenteral and oral


administration of sodium dihydrogen phosphate (NaH2PO4), popularly known as sodium
acid phosphate. Response to sodium acid phosphate therapy can be described as variable at
best and cure rate almost never exceeds 50%. Another flip side of the sodium acid
phosphate therapy is that treated animals become off feed and thus sustain a considerable
loss of body weight and milk yield. It follows that an alternative effective treatment without
these side effects is warranted.

Taking cues from observation of Indian investigators (Chugh S.K., R.M. Bhardwaj and
M.M. Mata, 1998. Lowered antioxidant status of red blood cells in post-parturient
hemoglobinuria of buffaloes. Vet. Res. Communication., 22: 385-388) that there is a
significant decrease in antioxidant status in parturient hemoglobinuria affected animals, we
recently tested the efficacy of an antioxidant therapy in the treatment of this disease. This de
novo therapy is based on intravenous administration of 2.4 to 4g of N-acetylcysteine in 1
liter of 5% dextrose followed by a similar dose per os 12 hours later. Ten grams of vitamin
C is also administered orally on daily basis. Of the 25 cows ad buffaloes treated thus far
with this regimen, 23 animals recovered and survived. In 2 animals, urine color returned to
normal but death ensued as the animals were recruited for treatment at an advanced stage of
the disease. A 2 days therapy with acetylcysteine + vitamin C generally suffices. This new
treatment is bereft of any discernable untoward effect and considerably less costly than the
standard treatment given ut supra. At the moment, results though seemingly encouraging
and much better than those with standard therapy should be construed as preliminary only
and lack the backing of carefully controlled scientific trials. As far as could be ascertained,
the use of acetylcysteine (a potent antidoxidant) has not as yet been evaluated in the
treatment of parturient hemoglobinuria in cow and buffaloes anywhere in the world. The
investigations conducted thus far were in a private capacity. Investigations aimed at
determining the mechanistic specificity of N-acetylcysteine through carefully controlled
clinical trial in hemoglobinuria and other oxidative stress associated clinical disorders of
animals are in the offing.

You might also like